GenomOncology adds new Vice President, Translational Medicine

News provided by

Jun 08, 2015, 06:05 ET

CLEVELAND, June 8, 2015 /PRNewswire/ -- GenomOncology today announced that Condie Carmack, Ph.D., has joined the company as Vice President, Translational Medicine. In this position, Dr. Carmack will report to Manuel Glynias, President, and CEO and will have responsibility for GenomOncology's products and services in oncology and their newest venture in constitutional medicine. Dr. Carmack brings 30 years of experience in the Life Science and Diagnostic industry with him to GO.

Dr. Carmack joins GenomOncology from Vela Diagnostic, where he served as Director of Oncology Programs since 2012. Prior to joining Vela, Dr. Carmack helped form the Cancer Genetics Laboratory (CGL) at Baylor College of Medicine with Dr. Marilyn Li, and served as General Manager there for two years. He also previously held positions at Agilent, Molecular Dynamics, and GenPharm.

Dr. Carmack scientific credentials include 25 peer-reviewed papers, one of which is the first published description of quantitative and multiplex PCR. Both of which are essential molecular techniques used everyday in clinical and research labs round the world.

Dr. Carmack received his undergraduate degree from University of California, in Irvine, CA. and his Ph.D. degree in Experimental Pathology from the University of Utah School of Medicine. He completed his postdoctoral training at the Fox Chase Cancer Center in Philadelphia, PA where he was awarded fellowships from the National Cancer Institute (NCI), Cancer Research Institute (CRI) and American Cancer Society (ACS).

About GenomOncology

GenomOncology is enabling precision medicine by translating next generation sequencing data into actionable information for clinicians and researchers. In collaboration with molecular pathologists and physicians, GenomOncology has developed the GO Clinical Workbench™, a decision support tool with a step-by-step workflow that takes raw data from the sequencer and translates the specific molecular profile of a sample into an actionable clinical report. GenomOncology's research platform allows scientists to analyze one or hundreds of genomes simultaneously to look for causal variants, reducing the time required to understand the genomic alterations that lead to new discoveries. More information can be found on the company's website at www.genomoncology.com.

Logo - http://photos.prnewswire.com/prnh/20140204/CL58248LOGO

SOURCE GenomOncology